Associations Between TGFA/TGFB3/MSX1 Gene Polymorphisms and Congenital Non-Syndromic Hearing Impairment in a Chinese Population

Jihong Du
Jianhua Deng

Background: The aim of this study was to investigate whether the TGFA/TGFB3/MSX1 gene polymorphisms and haplotypes lead to individual differences between congenital non-syndromic hearing impairment (NSHI) patients and normal people in a Chinese population and to analyze the risk factors for NSHI.

Material/Methods: Between December 2010 and September 2014, 343 congenital NSHI patients were recruited as cases, and 272 healthy subjects were recruited as controls. Denaturing high-performance liquid chromatography (DHPLC) was used to identify genotypes, SHEsis software was used to conduct gene linkage disequilibrium and haplotype analyses, and regression analysis was performed to identify risk factors for congenital NSHI.

Results: The distribution of genotype frequencies and allele frequencies of TGFA rs3771494, TGFB3 rs3917201 and rs2268626, and MSX1 rs3821949 and rs62636562 were significantly different between the case and the control groups (all \( P < 0.05 \)). TGFA/TGFB3/MSX1 gene rs3771494, rs1058213, rs3917201, rs2268626, rs3821949, and rs62636562 haplotype analysis showed that haplotype CCGTAC and TTACGT might be protective factors (both \( P < 0.001 \)), while TTGCCG might be a risk factor for the normal population (\( P < 0.001 \)). The other risk factors include paternal smoking, advanced maternal age, maternal sickness history, maternal contact with pesticides or similar drugs, maternal abortion history, maternal medication history, maternal passive smoking history during pregnancy, rs3771494 CT, rs2268626 CC and TC, and rs3821949 GG and AG genotypes were risk factors (all \( P < 0.05 \)), while maternal vitamin supplements during pregnancy, rs3917201 GA, rs62636562 TT and CT genotypes were protective factors for congenital NSHI (all \( P > 0.05 \)).

Conclusions: rs3771494, rs3917201, rs2268626, rs3821949 and rs62636562 might be associated with congenital NSHI.

MeSH Keywords: Polymorphism, Genetic • Transforming Growth Factor alpha • Transforming Growth Factor beta3

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/896527
Background

As a most common human sensory system defect, hearing impairment affects social, educational, and intelligence development, as well as speaking, expressing, comprehension, and psycho-social growth of individuals in a negative way [1]. Hearing impairment is a great threat to public health worldwide and nearly 10% people in the world have mild to moderate hearing impairment [2]. The incidence of congenital hearing impairment is 0.4–1.1 per 1000 births in the United States and 2 per 1000 births in Turkey [3]. There are 2 kinds of hearing impairment: syndromic hearing impairment with some other specific abnormalities accounting for 30%, and non-syndromic hearing impairment (NSHI) (70%) without additional abnormalities [4]. Both genetic and environmental factors are responsible for hearing impairment; 50% of hearing impairment in developed countries is attributable to genetic factors, and the majority is congenital NSHI [5]. Genetic factors are important for the pathogenesis of hearing impairment. Approximately 60% of congenital hearing impairment in developed countries has genetic causes; this proportion has been increasing due to the improvement of public health conditions and consequent reduction of hearing impairment linked to other causes [6]. Thus it is of great importance to study the genetic factors in congenital NSHI.

Belonging to the family of epidermal growth factors (EGFs), transforming growth factor alpha (TGFA-α), encoded by TGFA gene, can be activated by binding to cellular signaling-related receptors [7]. TGFA-α can function as pleiotropic molecules during development and pathological processes like cancer progression and wound healing [8]. The transforming growth factor-beta 3 (TGFB-β3) is a multifunctional peptide that exhibits diverse biological activities in cell growth and differentiation as well as regulation of extracellular matrix production [9]. TGFB3 gene encoding the TGFB-β3 protein is a candidate gene of great influence for cleft lip and palate in humans and has a broad spectrum of biological activities [10]. Human Msh homeobox 1 (MSX1) gene, mapped to chromosome 4, is expressed during early tooth development, and mutations of the MSX1 gene are involved in human isolated tooth agenesis with nail dysplasia or with cleft lip and palate [11]. MSX1 gene is abundantly expressed in inductive cell-cell interaction sites of the embryo and thus plays an important role during early development [12].

However, no study has been conducted on the associations between the TGFA/TGFB3/MSX1 gene polymorphisms and congenital NSHI. Thus, we aimed to identify the associations between the polymorphisms of TGFA/TGFB3/MSX1 genes and congenital NSHI, and to systematically study the risk factors in the development of the congenital NSHI.

Material and Methods

Study participants

Between December 2010 and September 2014, 343 congenital NSHI patients who were diagnosed by a comprehensive hearing examination and received treatment at Department of Otorhinolaryngology, the First People’s Hospital of Kunshan, Jiangsu province were enrolled to be the case group [13]. The patients’ mothers (n=310) were enrolled as the mother group, and the patients’ fathers (n=277) were enrolled as the father group. There were 248 complete core families (father + mother + child). Exclusion criteria were: (1) the patient’s hearing impairment was caused by infections in the middle ear, inner ear or intracalvarium, including non-suppurative otitis media, suppurative otitis media, otitis labyrinthica, and encephalitis; (2) the patient’s hearing impairment appeared after definite trauma to head, temporal bones, or ears; (3) the patient’s hearing impairment was caused by significant vibration-based damage of the inner ear; (4) the patients had syndromic hearing impairment accompanied with other organ or system diseases; (5) patients with conductive hearing impairment caused by unexplained causes; (6) the patient’s hearing impairment was due to inner ear vascular disease caused by diabetes, autoimmune diseases, etc.; (7) patients with hearing impairment accompanied with central nervous system diseases and mental disorders. A total of 272 healthy subjects who received physical examinations were enrolled as the control group. The study was in line with medical ethics standards and the standards of the Declaration of Helsinki [14], and approved by the Ethics Committee of the First People’s Hospital of Kunshan. Informed consents were received from patients or their families.

Data collection

The baseline data of all the study subjects were obtained through questionnaire surveys including gender, age, paternal smoking (PS), advanced maternal age (AMA), maternal sickness history (MSH), maternal contact with pesticides or similar drugs (MCPSD), maternal abortion history (MAH), maternal medication history (MMH), maternal vitamin supplements (MVS), and maternal passive smoking history (MPSH) during pregnancy.

Audiology diagnosis

Audiological tests included auditory brainstem response (ABR), auditory steady state response (ASSR), acoustic immittance, and pure tone audiometry (PTA) (only for people with older age and able to cooperate). GSI 70 hearing screening instrument (GSI, Illinois, USA) and brainstem auditory-evoked potential testing system (HIS Company, Colorado, USA) were used for measurements. ABR test was carried out in an electrically shielded soundproof room. Electrodes were in a silver-silver
chloride disk type, a recording electrode was placed in the middle of the forehead, and a reference electrode was placed to test ear mastoid with nasal root pointing to the ground. A short “click” sound was used to conduct stimuli with alternating waves at a superposition times of 1500 times, a filtering range of 30–1500 Hz, a scan time of 30 ms, and a maximum stimulation intensity of 105 dBnHL. The ASSR test used pure tone signal at a carrier wave frequency of 0.25–8 kHz, a modulation frequency of 70–110 Hz, and a maximum stimulation intensity of 120 dBHL, and the reaction signal was extracted by the computer software. Acoustic immittance testing was performed as follows: a probe of correct size was chosen and placed sealed in the external auditory canal, and the hole was on the right of the eardrum. The tympanogram was drawn at an initial pressure test of +200 daPa, a terminal pressure of –400 daPa, with a pressure change rate of 50 daPa/s and the direction from positive to negative. Suspicious individuals or individuals with abnormal acoustic immittance test results were given temporal bone thin layer CT scan at scan parameters of 120 kV, 180 mA, 1 mm thick, and a total of 20 layers. PTA was conducted in a standard soundproof room. According to GB/T 16403-1996 standard requirements, a rise method and a descent method were used to conduct PTA twice at 0.5–6 kHz, respectively. Two hearing threshold results were compared; the PTA hearing threshold difference at each frequency should be less than or equal to 5 dBHL to exclude pseudo-hearing impairment or exaggerated hearing impairment. Based on the standards recommended by the World Health Organization (WHO) in 2005 [15], hearing ability was determined depending on whether there existed hearing impairment, and the extent and nature of the hearing impairment (average hearing thresholds of 0.5 kHz, 1 kHz, 2 kHz, and 4 kHz) were used as standards. The degrees of hearing impairment were classified as: normal hearing; lower than or equal to 25 dBHL; mild hearing impairment: 26–40 dBHL; moderate hearing impairment: 41–70 dBHL; severe hearing impairment: 71–90 dBHL; and extremely severe hearing impairment: >90 dBHL. Syndromic hearing impairment referred to patients with hearing impairment as well as lesions in other locations, such as eyes, bone, kidney, and skin, while non-syndromic hearing impairment exhibited only hearing impairment.

### DNA extraction and genotyping

Peripheral blood samples of all study subjects were collected, mixed with glucose, citric acid and sodium citrate for anticoagulation, and stored at –80°C. Then, the peripheral blood samples were thawed slowly at 4°C, taken out to room temperature after the blood samples were completely thawed, and were carefully extracted when the temperature of the blood samples and room temperature were balanced. The blood clots and precipitates were carefully shattered in the extraction process to avoid the interference of subsequent extraction operation. DNA was extracted by DNA kit strictly following the instructions.

| SNP        | Primer sequences (5’-3’) | Amplification length |
|------------|--------------------------|----------------------|
| TGFA       |                          |                      |
| rs3771494  | F: ACGTGGAGTAGGAGGAGG    | 411 bp               |
|            | R: AAGCCAATGGTATTITTTA   |                      |
| rs1058213  | F: CGGTGCGATCAAGGTGCG    | 271 bp               |
|            | R: ACGCATTAATGGAAGATC    |                      |
| TGFB3      |                          |                      |
| rs3917201  | F: CAGTCTCCCTCTCTCG      | 314 bp               |
|            | R: TTAGCAACACTCTCTCT     |                      |
| rs2268626  | F: GTCTGACACACTGCTGGGACA | 332 bp               |
|            | R: TGGACAGTAGCTGTTCCAGG  |                      |
| MSX1       |                          |                      |
| rs3821949  | F: ACCCCCCGCTTCAAGGAGAT | 392 bp               |
|            | R: GTCCAAAGGTCAACAACC    |                      |
| rs62636562 | F: GCCTCCTCCTCCCTCTCG    | 300 bp               |
|            | R: AGGGACAAAGGAGGTGAAA   |                      |

**Table 1.** Primer sequences of TGFA/TGFB3/MSX1 gene.

SNP – single nucleotide polymorphisms; bp – base pairs; F – forward; R – reverse; TGFA – transforming growth factor alpha; TGFB3 – transforming growth factor-beta 3; MSX1 – Msh homeobox 1.
The DNA extraction steps were:

1. 1.0 ml of cell lysis buffer was extracted and loaded into a 2 ml Eppendorf tube (EP tube), and 400 μl blood sample was added into the corresponding EP tube. The mixture was mixed upside-down for 20-30 times until no blood clot blocks appeared, and centrifuged at 16,000 rpm for 4 min.

2. The supernatant was carefully discarded, and the remaining samples were drained by absorbent papers. We added 20 μl of protein denaturing buffer solution, and the mixture was shocked and mixed evenly immediately when the buffer solution was added each time until no cell clusters appeared; when the buffer solution was all added, we carefully checked whether there were incomplete cleavage samples.

3. The mixture was centrifuged briefly at 65°C water bath for 20 min, during which about 1/3 of the length of the tube or more was kept above the liquid surface water bath to prevent the lid from opening due to heating and water and other impurities from entering into the tube.

4. After brief centrifugation, 200 μl of isopropanol was added, and the mixture was turned up and down several times, until flocculent precipitate was observed.

5. The mixture was centrifuged at 16,000 rpm for 4 min, the supernatant was carefully discarded and drained by absorbent papers for 30 s, and then the white DNA precipitate can be observed at the bottom of the tube.

6. We added 200 μl 75% ethanol without stirring up the pellet precipitate, and the mixture was centrifuged at 16,000 rpm for 5 min.

7. The supernatant was carefully discarded and drained by absorbent papers for 20 s.

8. 110 μl DNA lysis buffer solution was added. The mixture was kept in the water bath at 65°C for 20 min, and placed in a shaker for 12 h. Finally, the electrophoresis was conducted, and the sample concentration was measured. The remaining samples were stored at –80°C.

Single-nucleotide polymorphisms (SNPs) information of TGFA, TGFB3, and MSX1 genes were retrieved from National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/Snp/), with TGFA gene rs3771494 and rs1058213, TGFB3 gene rs3917201 and rs2268626, and MSX1 gene rs3821949 and rs62636562 selected. Premier 5.0 software was used to design and verify polymerase chain reaction (PCR) amplification primers for each site, which were synthesized by Shanghai Sangon Biological Engineering Technology Co. (Shanghai, China). The primer sequences were shown in Table 1. PCR reactions were conducted in a Mastercycler gradient PCR instrument.
The reaction system consisted of: 100 ng of genomic DNA, 2.5 μl 10× PCR buffer, 1.5 μl dNTPs (each 2.5 mM), primers (10 pmol/μl) and Taq enzyme (2 U/μl), and water making the system volume 25 μl. The PCR protocol was: denaturation at 95°C for 5 min, 35 cycles of 95°C for 30 s, 52°C for 1 min, and 72°C for 30 min, followed by a final extension at 72°C for 5 min. After the completion of the reaction, 5 μl of the PCR product and 1 μl of 6× electrophoresis Loading Buffer were mixed evenly, and mixture was spotted on the agarose gel (ethidium bromide stained). The electrophoresis was conducted at 120V for 30 min. A gel imager was used to assess the amount and lengths of PCR amplification products. Another 25 μl of each PCR product was placed in 96-well plates of WAVE system for denaturing high performance liquid chromatography (DHPLC) analysis under partial denaturing conditions. The column temperature was 59.3°C and the mobile phase flow rate was 0.9 ml/min. All genotyping was performed in 2 steps: first, bi-peak DHPLC showed heterozygous genotype and the single peaks indicated the TT and CC genotypes; second, PCR products that presented single peak conducted an equal amount mixture with homozygous sample confirmed by sequencing, and then the mixture conducted DHPLC detection. The allelic mutations were confirmed by sequencing. The DHPLC profile patterns and sequencing results of PCR products are shown in Figures 1–3.

**Statistical analysis**

SPSS 21.0 statistical software (SPSS Inc, Chicago, IL, USA) was used for data analysis. The categorical data were presented as percentage or rate, and the genotype frequencies of the groups were compared using the chi-square test. Odds ratios (OR) and 95% confidence intervals (95%CI) were also calculated. SHEsis software analysis was used to analyze linkage disequilibrium and haplotype. Logistic regression analysis was used to identify the risk factors for the congenital NSHI patients. All tests used a 2-sided test, and a \( P < 0.05 \) indicated statistical significance.

**Results**

**Comparisons of baseline characteristics**

As shown in Table 2, there was no significant difference in age or gender between the case group and the control group (both \( P > 0.05 \)). The proportions of PS, AMG, MSH, MCPSD, MAH, MMH, and MPSH during pregnancy were significantly higher in the case group than those in the control group (all \( P < 0.05 \)). The proportion of MVP during pregnancy was significantly lower in the case group (\( P < 0.05 \)).
Hardy-Weinberg genetic equilibrium law showed that genotypes of all the sites in the control group were in line with the Hardy-Weinberg genetic equilibrium (\(P > 0.05\)), thus the controls can be considered to have been selected from a balanced population with group representation. Genotype and allele frequencies of \(\text{TGFA}\) rs3771494 were significantly different in the case group, the father group, and the mother group from those in the case group (all \(P < 0.05\)). The frequencies of C and T alleles of \(\text{TGFA}\) rs3771494 showed significant differences in the control group and the case group (both \(P < 0.05\)), and T allele might be a risk for congenital NSHI (OR=1.538, 95%CI=[1.199–1.972]). There was no significant difference in the \(\text{TGFA}\) rs1058213 genotype or allele frequency between the control group and the case group, or between the father group and the control group (all \(P > 0.05\)), while the \(\text{TGFA}\) rs1058213 genotype and allele frequencies showed significant differences in the mother group and the control group (both \(P < 0.05\)) (Table 3).

Compared with the control group, the genotype and allele frequencies of \(\text{TGFB3}\) rs3917201 were significantly different in the case group (both \(P < 0.05\)), but showed no significant difference in the father or the mother group (all \(P > 0.05\)). The frequencies of G and A alleles of \(\text{rs3917201}\) were significantly different in the control group and the case group (both \(P < 0.05\)), and A allele carrier had lower risk of congenital NSHI (OR=0.623, 95%CI=[0.484, 0.802]). The control group and the case group, the control group and the father group, and the control group and the mother group showed significant differences in \(\text{TGFB3}\) rs2268626 genotype and allele frequencies (all \(P < 0.05\)). T and C alleles of rs2268626 showed significant differences between the control group and the case group (both \(P < 0.05\)), and C allele might have increased congenital NSHI risk (OR=1.705, 95%CI=[1.322, 2.197]) (Table 4).

Compared with the control group, the genotype and allele frequencies of \(\text{MSXI}\) rs3821949 showed significant differences in the case group, the father group, and the mother group (all \(P < 0.05\)). The frequencies of A and G alleles of \(\text{rs3821949}\) were significantly different between the control group and the case group (both \(P < 0.05\)), and G allele might have increased the risk of congenital NSHI (OR=1.619, 95%CI=[1.260, 2.080]). The genotype and allele frequencies of \(\text{MSXI}\) rs62636562 were
Table 2. Comparisons of baseline characteristics between the case group and the control group.

|                      | Case group | Control group | t/χ²  | P    |
|----------------------|------------|---------------|-------|------|
| **Age**              | 10.8±2.4   | 11.1±2.0      | 1.553 | 0.121|
| **Gender**           |            |               |       |      |
| Male                 | 138        | 169           | 2.257 | 0.133|
| Female               | 110        | 103           |       |      |
| **PS**               |            |               |       |      |
| Yes                  | 159        | 140           | 8.484 | 0.004|
| No                   | 89         | 132           |       |      |
| **AMA (more than 35 years old)** |        |               |       |      |
| Yes                  | 172        | 146           | 13.42 | 0.001|
| No                   | 76         | 126           |       |      |
| **MSH**              |            |               |       |      |
| Yes                  | 168        | 10            | 192.3 | <0.001|
| No                   | 80         | 262           |       |      |
| **MCPSD**            |            |               |       |      |
| Yes                  | 128        | 80            | 26.64 | <0.001|
| No                   | 120        | 192           |       |      |
| **MAH**              |            |               |       |      |
| Yes                  | 132        | 42            | 83.18 | <0.001|
| No                   | 116        | 230           |       |      |
| **MMH**              |            |               |       |      |
| Yes                  | 135        | 5             | 182.4 | <0.001|
| No                   | 113        | 267           |       |      |
| **MVS**              |            |               |       |      |
| Yes                  | 15         | 114           | 89.45 | <0.001|
| No                   | 233        | 158           |       |      |
| **MPSH**             |            |               |       |      |
| Yes                  | 176        | 140           | 13.88 | 0.001|
| No                   | 72         | 132           |       |      |

PS – paternal smoking; AMA – advanced maternal age; MSH – maternal sickness history; MCPSD – maternal contact with pesticides or similar drugs; MAH – maternal abortion history; MMH – maternal medication history; MVS – maternal vitamin supplements; MPSH – maternal passive smoking history.
Table 3. Comparisons of genotype and allele frequencies of TGFA rs3771494 and rs1058213.

| Genotypes | rs3771494 | Father | Mother | Case | Control |
|-----------|-----------|--------|--------|------|---------|
| rs3771494 | CC        | 56 (22.58) | 53 (21.37) | 57 (22.98) | 84 (30.88) |
|           | TT        | 118 (47.58) | 115 (46.37) | 125 (46.37) | 102 (37.50) |
|           | CT        | 74 (29.84) | 80 (32.26) | 66 (30.65) | 86 (31.62) |
|           | χ²        | 6.570* | 7.532* | 9.044* | Ref. |
|           | P         | 0.037* | 0.023* | 0.011* | – |
|           | C         | 186 (37.50) | 186 (37.50) | 180 (36.29) | 254 (46.69) |
|           | T         | 310 (62.50) | 310 (62.50) | 316 (63.71) | 290 (53.31) |
|           | χ²        | 8.980* | 8.980* | 11.54* | Ref. |
|           | P         | 0.003* | 0.003* | 0.001* | – |
|           | C vs. T  | OR | 1.460* | 1.333* | 1.538* | Ref. |
|           | 95%CI     | 1.139–1.870* | 1.043–1.702* | 1.199–1.972* | – |
| rs1058213 | CC        | 68 (27.42) | 73 (29.44) | 73 (29.44) | 82 (30.15) |
|           | TT        | 54 (21.77) | 30 (12.10) | 47 (18.95) | 58 (21.32) |
|           | CT        | 126 (50.81) | 145 (58.46) | 128 (51.61) | 132 (48.53) |
|           | χ²        | 0.482* | 8.953* | 0.630* | Ref. |
|           | P         | 0.923* | 0.011* | 0.730* | – |
|           | C         | 262 (52.82) | 291 (58.67) | 274 (45.97) | 296 (54.41) |
|           | T         | 234 (47.18) | 205 (41.33) | 222 (54.03) | 248 (45.59) |
|           | χ²        | 0.264* | 1.913* | 0.072* | Ref. |
|           | P         | 0.608* | 0.167* | 0.788* | – |
|           | C vs. T  | OR | 1.066* | 0.841* | 0.967* | Ref. |
|           | 95%CI     | 0.835–1.361* | 0.658–1.075* | 0.757–1.235* | – |

Ref. – references; OR – odds ratio; 95%CI – 95% confident interval; * Compared with the control group; TGFA – transforming growth factor alpha.
Table 4. Comparisons of genotype and allele frequencies of TGFB3 rs3917201 and rs2268626.

| Genotypes | Father | Mother | Case | Control |
|-----------|--------|--------|------|---------|
| rs3917201 |        |        |      |         |
| GG        | 91 (36.69) | 98 (39.52) | 118 (47.58) | 89 (32.72) |
| AA        | 42 (16.94) | 42 (16.94) | 36 (14.52) | 60 (22.06) |
| GA        | 115 (46.37) | 108 (43.54) | 94 (37.90) | 123 (46.22) |
| \( \chi^2 \) | 2.365* | 3.483* | 12.860* | Ref. |
| \( P \) | 0.306* | 0.323* | 0.002* | -- |
| G         | 297 (59.88) | 304 (61.29) | 330 (66.53) | 301 (55.33) |
| A         | 199 (40.12) | 192 (38.71) | 166 (33.47) | 243 (44.67) |
| \( \chi^2 \) | 2.196* | 3.787* | 13.640* | Ref. |
| \( P \) | 0.138* | 0.151* | 0.001* | -- |
| G vs. A   |        |        |      |         |
| OR        | 0.830* | 0.782* | 0.623* | Ref. |
| 95%CI     | 0.648–1.060* | 0.611–1.002* | 0.484–0.802* | -- |
| rs2268626 |        |        |      |         |
| TT        | 59 (23.79) | 56 (22.58) | 48 (19.35) | 70 (11.03) |
| CC        | 124 (50.00) | 122 (49.19) | 139 (56.05) | 102 (38.97) |
| TC        | 65 (26.21) | 70 (28.23) | 61 (24.60) | 100 (50.00) |
| \( \chi^2 \) | 9.416* | 7.544* | 18.16* | Ref. |
| \( P \) | 0.009* | 0.023* | 0.001* | -- |
| T         | 173 (48.79) | 182 (47.18) | 157 (40.89) | 240 (36.03) |
| C         | 313 (51.21) | 314 (52.82) | 339 (52.62) | 304 (63.97) |
| \( \chi^2 \) | 7.759* | 2.435* | 17.080* | Ref. |
| \( P \) | 0.005* | 0.015* | < 0.001* | -- |
| T vs. C   |        |        |      |         |
| OR        | 1.350* | 1.362* | 1.705* | Ref. |
| 95%CI     | 1.053–1.732* | 1.062–1.747* | 1.322–2.197* | -- |

Ref. – references; OR – odds ratio; 95%CI – 95% confident interval; * Compared with the control group; TGFB3 – transforming growth factor-beta 3.
| Genotypes | Father | Mother | Case | Control |
|-----------|--------|--------|------|---------|
| rs3821949 |        |        |      |         |
| AA        | 47 (18.95) | 46 (18.55) | 45 (18.15) | 77 (28.31) |
| GG        | 113 (45.56) | 128 (51.61) | 123 (49.59) | 100 (36.76) |
| GA        | 88 (35.48) | 74 (29.84) | 80 (32.26) | 95 (34.93) |
| $\chi^2$  | 7.227* | 12.780* | 10.970* | Ref. |
| $P$       | 0.027* | 0.002* | 0.004* | – |
| A         | 182 (36.69) | 166 (33.47) | 170 (34.27) | 249 (45.77) |
| G         | 314 (63.31) | 330 (66.53) | 326 (65.73) | 295 (54.23) |
| $\chi^2$  | 8.811* | 16.380* | 14.260* | Ref. |
| $P$       | 0.003* | < 0.001* | 0.001* | – |
| A vs. G   |        |        |      |         |
| OR        | 1.456* | 1.678* | 1.619* | Ref. |
| 95%CI     | 1.136~1.867* | 1.305~2.158* | 1.260~2.080* | – |
| rs62636562|        |        |      |         |
| CC        | 83 (33.47) | 90 (36.29) | 90 (36.29) | 100 (36.76) |
| TT        | 35 (14.11) | 50 (20.16) | 36 (14.52) | 87 (31.99) |
| CT        | 130 (52.42) | 108 (43.55) | 122 (49.19) | 85 (31.25) |
| $\chi^2$  | 32.120* | 12.180* | 27.240* | Ref. |
| $P$       | < 0.001* | 0.002* | < 0.001* | – |
| C         | 296 (59.68) | 288 (58.06) | 302 (40.89) | 259 (61.58) |
| T         | 200 (40.32) | 208 (41.94) | 194 (39.11) | 285 (38.42) |
| $\chi^2$  | 15.180* | 11.370* | 18.410* | Ref. |
| $P$       | < 0.001* | 0.001* | < 0.001* | – |
| C vs. T   |        |        |      |         |
| OR        | 0.614* | 0.656* | 0.584* | Ref. |
| 95%CI     | 0.480~0.785* | 0.514~0.839* | 0.456~0.747* | – |

Ref. – references; OR – odds ratio; 95%CI – 95% confident interval; * Compared with the control group; MSXI – Msh homeobox 1.
Table 6. Linkage disequilibrium analysis of TGFA/TGFB3/MSX1 gene SNPs.

| SNP        | D'  | r²  |
|------------|-----|-----|
| rs1058213  | 0.977/0.564 | 1.000/0.464 |
| rs3917201  | 0.937/0.758 | 0.903/0.769 |
| rs2268626  | 0.994/0.546 | 0.994/0.546 |
| rs3821949  | 0.977/0.564 | 1.000/0.464 |
| rs62636562 | 0.977/0.564 | 1.000/0.464 |

SNP – single nucleotide polymorphisms; D – Linkage disequilibrium coefficient; r – correlation coefficient; TGFA – transforming growth factor alpha; TGFB3 – transforming growth factor-beta 3; MSX1 – Msh homeobox 1.

Table 7. Comparisons of haplotypes of TGFA/TGFB3/MSX1 gene between the case group and the control group.

| Haplotype | Case (freq.) | Control (freq.) | \( \chi^2 \) | \( P \) | OR (95%CI) |
|-----------|--------------|-----------------|------------|-----|---------|
| CCGCCGC   | 18.00 (0.036) | 10.00 (0.018)   | 3.040      | 0.081 | 1.983 (0.906–4.342) |
| CCGTAC    | 151.00 (0.304) | 224.96 (0.414) | 15.394 | <0.001 | 0.593 (0.456–0.770) |
| TTACGT    | 128.06 (0.258) | 211.96 (0.390) | 22.743 | <0.001 | 0.521 (0.398–0.682) |
| TTGCCGC   | 34.41 (0.069) | 10.00 (0.018)   | 16.138 | <0.001 | 3.936 (1.924–8.053) |

Freq. – frequency; OR – odds ratio; 95%CI – 95% confident interval; TGFA – transforming growth factor alpha; TGFB3 – transforming growth factor-beta 3; MSX1 – Msh homeobox 1.

significantly different between the control group and the case group, the control group and the father group, and the control group and the mother group (all \( P < 0.05 \)). C and T alleles of rs62636562 showed different distributions between the control group and the case group (both \( P < 0.05 \)), and T allele might have decreased the risk of congenital NSHI (\( \text{OR}=0.584, 95\%\text{CI}=0.456–0.747 \)) (Table 5).

Haplotype analysis

SHEsis analysis software was used to analyze the linkage disequilibrium and haplotype of the 6 sites of rs3771494, rs1058213, rs3917201, rs2268626, rs3821949, and rs62636562. The results showed that there was strong linkage disequilibrium between these 6 sites (Table 6). Haplotypes with a frequency less than 3% were excluded from the haplotype analysis, thus the CCGCCGC haplotype was excluded. Haplotype CCGTAC and TTACGT might be protective (both \( P < 0.001 \)), while haplotype TTGCCGC might be a risk factor for the normal population (\( P < 0.001 \)) (Table 7).

Logistic regression analysis

Whether study participants (case group and control group) had congenital NSHI was regarded as the dependent variable, whereas PS, AMG, MSH, MCPSD, MAH, MMH, MVS, and MPSH during pregnancy, along with rs3771494, rs3917201, rs2268626, rs3821949, and rs62636562 mutant and non-mutant genotypes were taken as the independent variables of the logistic regression model. Multivariable non-conditional logistic regression analysis was conducted with regression coefficients estimated and OR and 95%CI calculated. OR >1 indicated the corresponding factor to be a risk factor, while OR <1 indicated protective factors. PS, AMG, and MSH, MCPSD, MAH, MMH, and MPSH during pregnancy were risk factors for congenital NSHI (all \( P < 0.05 \); OR >1), while MVS during pregnancy was a protective factor for congenital NSHI (\( P < 0.05 \), OR <1). Besides, rs3771494 CT genotype, rs2268626 CC and TC genotypes, and rs3821949 GG and AG genotypes were risk factors for congenital NSHI (rs3771494 CT: \( \text{OR}=4.089, 95\%\text{CI}=(1.393,11.998), P=0.010; \) rs2268626 CC: \( \text{OR}=4.288,95\%\text{CI}=(4.288,49.697), P<0.001; \) rs2268626 TC: \( \text{OR}=8.193,95\%\text{CI}=(2.193,29.925), P=0.002; \) rs3821949 GG: \( \text{OR}=3.931,95\%\text{CI}=(1.163,10.018), P=0.025; \) rs3821949 AG: \( \text{OR}=4.346,95\%\text{CI}=(1.395,13.543), P=0.011; \) while rs3917201 GA genotype, rs62636562 TT and CT genotypes were protective factors (rs3917201 GA: \( \text{OR}=0.098,95\%\text{CI}=(0.031,0.308), P<0.001; \) Table 8).
Table 8. Multivariate non-conditional logistic regression analysis for congenital NSHI.

| Variable                  | B     | S.E.  | Wald   | df | Sig.  | OR    | 95% CI       |
|---------------------------|-------|-------|--------|----|-------|-------|--------------|
|                           |       |       |        |    |       | Lower | Upper        |
| PS                        | 0.908 | 0.429 | 4.471  | 1  | 0.034 | 2.479 | 1.069 - 5.750 |
| AMA                       | 0.917 | 0.424 | 4.673  | 1  | 0.031 | 2.502 | 1.089 - 5.748 |
| MSH                       | 4.914 | 0.601 | 66.917 | 1  | <0.001 | 136.213 | 41.963 - 442.153 |
| MCPSD                     | 1.198 | 0.523 | 5.242  | 1  | 0.022 | 3.313 | 1.188 - 9.235 |
| MAH                       | 2.474 | 0.475 | 27.131 | 1  | <0.001 | 11.869 | 4.679 - 30.108 |
| MMH                       | 5.288 | 0.874 | 36.631 | 1  | <0.001 | 198.000 | 35.721 - 1097.491 |
| MVS                       | -2.664| 0.617 | 18.672 | 1  | <0.001 | 0.070  | 0.021 - 0.233 |
| MPSH                      | 0.966 | 0.493 | 3.836  | 1  | 0.050 | 2.627  | 0.999 - 6.909 |
| rs3771494                 | 6.655 |       | 2      |    | 0.036 |       |              |
| rs3771494 (1)             | 1.103 | 0.593 | 3.460  | 1  | 0.063 | 3.012  | 0.943 - 9.626 |
| rs3771494 (2)             | 1.408 | 0.549 | 6.574  | 1  | 0.010 | 4.089  | 1.393 - 11.998 |
| rs3917201                 | 11.908|       | 2      |    | 0.003 |       |              |
| rs3917201 (1)             | -0.491| 0.562 | 0.763  | 1  | 0.382 | 0.612  | 0.203 - 1.842 |
| rs3917201 (2)             | -1.642| 0.477 | 11.836 | 1  | 0.001 | 0.194  | 0.076 - 0.493 |
| rs2268626                 | 18.515|       | 2      |    | <0.001 |       |              |
| rs2268626 (1)             | 2.681 | 0.625 | 18.396 | 1  | <0.001 | 14.598 | 4.288 - 49.697 |
| rs2268626 (2)             | 2.092 | 0.667 | 9.844  | 1  | 0.002 | 8.100  | 2.193 - 29.225 |
| rs3821949                 | 6.937 |       | 2      |    | 0.031 |       |              |
| rs3821949 (1)             | 1.228 | 0.549 | 4.995  | 1  | 0.025 | 3.413  | 1.163 - 10.018 |
| rs3821949 (2)             | 1.469 | 0.580 | 6.419  | 1  | 0.011 | 4.346  | 1.395 - 13.543 |
| rs62636562                | 16.063|       | 2      |    | <0.001 |       |              |
| rs62636562 (1)            | -1.077| 0.482 | 4.995  | 1  | 0.025 | 0.341  | 0.132 - 0.876 |
| rs62636562 (2)            | -2.326| 0.585 | 15.791 | 1  | <0.001 | 0.098  | 0.031 - 0.308 |

NSHI – non-syndromic hearing impairment; B – partial regression coefficient; S.E. – standard error; df – degree of freedom; Sig. – significance; OR – odds ratio; 95%CI – 95% confidence interval; PS – parental smoking; AMA – advanced maternal age; MSH – maternal sickness history; MCPSD – maternal contact with pesticides or similar drugs; MAH – maternal abortion history; MMH – maternal medication history; MVS – maternal vitamin supplements; MPSH – maternal passive smoking history; rs3771494 (1), the comparison result between CC and TT genotype; rs3771494 (2) the comparison result between CT and CC genotype; rs3917201 (1), the comparison result between AA and GG genotype; rs3917201 (2), the comparison result between GA and GG genotype; rs2268626 (1), the comparison result between CC and TT genotype; rs2268626 (2), the comparison result between TC and CC genotype; rs3821949 (1), the comparison result between GG and AA genotype; rs3821949 (2), the comparison result between AG and AA genotype; rs62636562 (1), the comparison result between CC and TT genotype; rs62636562 (2), the comparison result between CT and CC genotype.
Discussion

For the first time, our study investigated the associations between the TGFA/TGFB3/MSX1 gene polymorphisms and congenital NSHI. Our main results showed that the distribution of allele and genotype frequencies of rs3771494 in TGFA gene, rs3917201 and rs2268626 in TGFB3 gene, and rs3821949 and rs62636562 in MSX1 gene were statistically different between the case and control groups. Haplotype analysis further confirmed that CCGTAC and TTACGT might be protective factors, while haplotype TTGCGC might be a risk factor for the normal population, indicating that these 5 sites might cooperate together to participate in the development of congenital NSHI.

The delivery of TGF-α to the cell surface and cleavage from the cell surface are both critical to TGF-α-mediated EGF receptor activation and are disrupted in many diseases [7]. The TGFA/EGFR autocrine signaling loop sustained the proliferation of papillary thyroid carcinoma cells, and TGFA transcripts were significantly higher in papillary thyroid carcinoma metastases and trended upwards with tumor stage, indicating that TGFA was associated with advanced tumor stage and poor clinical outcome [16]. EGF/TGF-α is believed to regulate palatal epithelial cell proliferation and differentiation, and the mutations in the TGFA gene might contribute to cleft lip or palate [17,18]. Furthermore, possible effects of gene-environment interaction between markers in TGFA and maternal smoking, alcohol consumption, and vitamin use were found [19].

TGF-β was revealed to be involved in proliferation, differentiation, motility, adhesion, and death of normal cells and it can act as a promoter of tumors, invasion, and metastasis due to its role in stimulating angiogenesis and epithelial to mesenchymal transformation [20,21]. TGF-β was also found to play a role in embryonic development and wound healing in many molecular pathways, including tissue repair [22]. In addition, SfaN1 polymorphism in TGFB3 gene may be a good screening marker for patients with non-syndromic cleft lip with or without cleft palate [23]. Mutations in TGFB3 are also responsible for aortic aneurysmal disease [24].

As transcriptional repressors, MSX1 regulatory proteins are widely expressed in many organs and are involved in the craniofacial and limb modulation and nervous system development [25]. MSX1 is especially expressed at epithelial–mesenchymal interaction in odontogenesis during the bud and cap stages of tooth development, and the C terminus of MSX1 may play an important role in tooth agenesis [26].

Taken together, TGFA/TGFB3/MSX1 genes are important in embryonic development and in the process of organ development, thus TGFA/TGFB3/MSX1 gene polymorphisms might be related with congenital NSHI. Logistic regression analysis further confirmed that rs3771494 CT genotype, rs2268626 CC and TC genotypes, and rs3821949 GG and AG genotypes were risk factors, while rs3917201 GA genotype, rs62636562 TT and CT genotypes were protective factors for congenital NSHI.

Another important result of our logistic regression analysis showed that paternal and maternal unhealthy lifestyle and poor maternal health condition and medication during pregnancy might increase the risk of congenital NSHI, while maternal vitamin supplements during pregnancy may prevent congenital NSHI. Prenatal smoke exposure causes obstetrical complications and might be independently associated with higher pure-tone hearing thresholds and an increase in the incidence of unilateral low-frequency hearing impairment, suggesting that in utero exposure to tobacco smoking may harm the auditory system [27]. Infants that have been prenatally exposed to cocaine are also at increased risk for hearing impairment because cocaine can alter neurosensory transmission through the brainstem and might cause damage to the organ of Corti during critical periods of development, which is important for transducing mechanical sound vibrations into nerve impulses [28]. A case report showed that cisplatin used during the second and third trimesters of pregnancy might lead to fetal ototoxicity and severe hearing loss [29]. It has also been reported that vitamin A is an important factor for normal fetal inner ear development, and vitamin A deficiency exacerbates the severity of ear infections and even hearing loss [30].

Conclusions

Our study showed that TGFA/TGFB3/MSX1 gene polymorphisms were associated with congenital NSHI. CCGTAC and TTACGT haplotypes might be protective factors, while TTGCGC haplotype might be a risk factor for congenital NSHI. In addition, environmental factors, such as smoking, maternal sickness history, maternal medication history, and maternal vitamin supplements, are also associated with the development of congenital NSHI. Thus, the pathogenesis of congenital NSHI is a combination of both genetic and environmental effects. Further investigations are needed to define the detailed mechanisms of the associations between these 3 gene polymorphisms and congenital NSHI.

Acknowledgments

We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.

Competing interests

The authors have declared that no competing interests exist.
References:

1. Dai ZY, Sun BC, Huang SS et al: Correlation analysis of phenotype and genotype of GJB2 in patients with non-syndromic hearing loss in China. Gene, 2015; 570: 272–76
2. Liu F, Hu J, Xia W et al: Exome sequencing identifies a mutation in EYA4 as a novel cause of autosomal dominant non-syndromic hearing loss. PLoS One, 2015; 10: e0126602
3. Karamert R, Bayazit YA, Altinyay S et al: Association of GJB2 gene mutation with cochlear implant performance in genetic non-syndromic hearing loss. Int J Pediatr Otorhinolaryngol, 2011; 75: 1572–75
4. Coco M, Sahvelini F, Greco F et al: Significance of heterozygosis M34T mutation of GJB2 gene in non-syndromic congenital deafness. Retrospective analysis of 12,472 samples of amniotic fluid. J Prenat Med, 2013; 7: 56–58
5. Patel K, Giese AP, Grossheim JM et al: A Novel C-terminal CIB2 (calcium and integrin binding protein 2) mutation associated with non-syndromic hearing loss in a Hispanic family. PLoS One, 2015; 10: e0133082
6. Salvago P, Martines E, La Mattina E et al: Distribution and phenotype of GJB2 mutations in 102 Sicilian patients with congenital non syndromic sensorineural hearing loss. Int J Audiol, 2014; 53: 558–63
7. Singh B, Coffey Ri: From wavy hair to naked proteins: the role of transforming growth factor alpha in health and disease. Semin Cell Dev Biol, 2014; 28: 12–21
8. Zhang L, Zhan Z, Wu J et al: Relationship between EGF, TGFA, and EGFR gene polymorphisms and traditional Chinese medicine ZHENG in gastric cancer. Evid Based Complement Altern Med, 2013; 2013: 71071
9. Norian JM, Malik M, Parker CY et al: A Novel C-terminal CIB2 (calcium and integrin binding protein 2) mutation associated with non-syndromic hearing loss in a Hispanic family. PLoS One, 2015; 10: e0133082
10. Saleem S, Rajendran R, Moinak B et al: Evidence for transforming growth factor-beta 3 gene polymorphism in non-syndromic cleft lip and palate patients from Indian sub-continent. Med Oral Patol Oral Cir Bucal, 2012; 17: e197–200
11. Tatematsu T, Kimura M, Nakashima M et al: An aberrant splice acceptor site due to a novel intronic nucleotide substitution in MSX1 gene is the cause of congenital tooth agenesis in a Japanese family. PLoS One, 2015; 10: e0212287
12. Shetty S, Takahashi T, Matsui H et al: Transcriptional autorepression of Msx2 gene is mediated by interactions of Msx1 protein with a multi-protein transcriptional complex containing TATA-binding protein, Sp1 and cAMP-response-element-binding protein-binding protein (CBP/p300). Biochem J, 1999; 339(Pt 3): 751–58
13. Gong WX, Gong RZ, Zhao B: HRC and MRR findings in X-linked non-syndromic deafness patients with a POU3F4 mutation. Int J Pediatr Otorhinolaryngol, 2014; 78: 1756–62
14. M PN: World Medical Association publishes the Revised Declaration of Helsinki. Natl Med J India, 2014; 27: 56
15. Baltussen R, Smith A: Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: Mathematical modelling study. BMJ, 2012; 344: e615
16. Degl’Innocenti D, Alberti C, Castellano G et al: Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas. PLoS One, 2010; 5: e12701
17. Feng C, Zhang E, Duan W et al: Association between polymorphism of TGFA Taq I and cleft lip and/or palate: a meta-analysis. BMC Oral Health, 2014; 14: 88
18. Souza LT, Kowalski TW, Vanz AP et al: TGFA/Taq I polymorphism and environmental factors in non-syndromic oral clefts in Southern Brazil. Braz Oral Res, 2012; 26: 431–35
19. Sull JW, Liang KY, Hetmanski JB et al: Evidence that TGFA influences risk to cleft lip with/without cleft palate through unconventional genetic mechanisms. Hum Genet, 2009; 126: 385–94
20. Mezaki Y, Morii M, Yoshikawa K et al: Elevated expression of transforming growth factor beta3 in carbon tetrachloride-treated rat liver and involvement of retinoid signaling. Int J Mol Med, 2012; 29: 13–23
21. Walker L, Millena AC, Strong N, Khan SA: Expression of TGFBeta3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway. Clin Exp Metastasis, 2013; 30: 13–23
22. Le M, Naridze R, Morrison J et al: Transforming growth factor Beta 3 is required for excisional wound repair in vivo. PLoS One, 2012; 7: e48040
23. Ulucan K, Bayraktar N, Parmaksiz E et al: Transforming growth factor-beta3 intron 5 polymorphism as a screening marker for non-syndromic cleft lip with or without cleft palate. Mol Med Rep, 2012; 6: 1465–67
24. Bertoli-Avella AM, Gills E, Morisaki H et al: Mutations in a TGF-beta ligand, TGFB3, cause syndromic aeroeurythms and dissections. J Am Coll Cardiol, 2015; 65: 1324–36
25. Cardoso ML, Bezerra JF, Oliveira GH et al: MSX1 gene polymorphisms in non-syndromic cleft lip and/or palate. Oral Dis, 2013; 19: 507–12
26. Alfwaz S, Plagnol V, Wong FS, Kelsell DP: A novel frameshift MSX1 mutation in a Saudi family with autosomal dominant premolar and third molar agenesis. Arch Oral Biol, 2015; 60: 982–88
27. Weitzman M, Govil N, Liu YH, LaWani AK: Maternal prenatal smoking and hearing loss among adolescents. JAMA Otolaryngol Head Neck Surg, 2013; 139: 669–77
28. Tan-Laxa MA, Sison-Switala C, Rintelman W, Ostrea EM Jr.: Abnormal auditory brainstem response among infants with prenatal cocaine exposure. Pediatrics, 2004; 113: 357–60
29. Geijteman EC, Wensveen CW, Duvekot JJ, van Zuylen L: A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy. Obstet Gynecol, 2012; 124: 454–56
30. Emmett SD, West KP Jr.: Gestational vitamin A deficiency: a novel cause of sensorineural hearing loss in the developing world? Med Hypotheses, 2014; 82: 6–10